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a b s t r a c t   
Remdesivir (REM) is the first antiviral drug (Veklury™) approved by the Food and Drug Administration for 
the therapy of COVID-19. Due to its poor water solubility, the preparation of Veklury™ requires a suitable 
solubilizing excipient at pH 2 conditions. For this purpose, the final formulation contains the randomly 
substituted sulfobutylether-β-cyclodextrin (SBEβCD) as a complexing agent. Herein, extensive NMR spec-
troscopic study with various cyclodextrin (CD) derivatives were conducted to understand the interactions in 
SBEβCD - REM systems at the molecular level. The pKa value of REM has been determined experimentally for 
the first time, as the protonation state of the aminopyrrolo-triazine moiety can play a key role in CD-REM 
inclusion complex formation as SBEβCD has permanent negative charges. The UV-pH titration experiments 
yielded a pKa of 3.56, thus the majority of REM bears a positive charge at pH 2.0. 
NMR experiments were performed on β- and γCD derivatives to determine complex stabilities, stoi-
chiometries and structures. The stability constants were determined by nonlinear curve fitting based on 1H 
NMR titrations at pH 2.0, while Job’s method was used to determine the stoichiometries. βCD complexes 
were one order of magnitude more stable than their γCD counterparts. Sulfobutylation resulted in a sig-
nificant increase in stability and the single isomer derivatives showed unexpectedly high stability values 
(logK = 4.35 for REM - per-6-SBEβCD). In the case of βCDs, the ethylbutyl-moiety plays a key role in com-
plexation immersing into the βCD cavity, while the phenoxy-moiety overtakes and drives the inclusion of 
REM in the case of γCDs. This is the first comprehensive study of REM-CD complexation, allowing the design 
of new CD derivatives with tailored stabilities, thereby aiding the formulation or production and even the 
analytical characterization of REM. 
© 2021 The Author(s). Published by Elsevier B.V. 
CC_BY_NC_ND_4.0   
1. Introduction 
In December 2019, Wuhan, China, SARS-CoV-2 (Severe Acute 
Respiratory Syndrome Coronavirus 2) caused an outbreak of a severe 
respiratory illness which was then arguably declared to be one of the 
most serious health concerns that has impacted the entire world  
[1,2]. Since the beginning of the pandemic, several investigational 
drugs have been explored. Among these agents, remdesivir (REM) 
was the first antiviral agent (Veklury™) approved by US Food and 
Drug Agency for the treatment of COVID-19 [3]. REM has broad 
antiviral activity against mRNA viruses, originally developed to treat 
hepatitis C and Ebola infections [4]. It is a monophosphoramidate 
prodrug (Fig. 1A), that is metabolically transformed into the phar-
macologically active nucleoside, a triphosphate analog. The active 
metabolite competes with adenosine phosphate and acts as an RNA- 
dependent RNA polymerase inhibitor [5]. Due to REM’s high first 
pass liver metabolism, it cannot be applied orally [6], thus an in-
travenous infusion in the form of a parenteral solution is the only 
approved administration route. REM is poorly soluble in water 
(0.028 mg/mL) therefore solubilizing excipients are required to for-
mulate the product. At an early stage of the formulation a randomly 
substituted multicomponent mixture of sulfobutylether-beta-cyclo-
dextrin (SBEβCD, DS ~ 6.5) is used at pH 2.0 for this purpose [7]. The 
permanently negatively charged SBEβCD is able to complex REM 
through non-covalent intermolecular interactions, thereby sig-
nificantly enhances its solubility. Cyclodextrins (CDs) are cyclic oli-
gosaccharides built of D-glucopyranose units (α-, β- and γ-CDs - six, 
seven and eight glucose units) linked via α-1,4-glycosidic bonds. As a 
result, they have a lipophilic inner cavity and a hydrophilic outer 
surface [8]. This particular structure enables reversible inclusion 
complex formation with guest molecules [9]. Synthetic modification 
of the hydroxyl groups of the glucopyranose units offers numerous 
possibilities for the preparation of various hosts for drug formula-
tion. Fig. 1B shows the structure of the CDs included in our study. In 
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the present article several β- and γCD derivatives were used to 
characterize REM’s charge-dependent molecular encapsulation. In 
order to understand charge-dependent behavior of REM, its experi-
mental pKa value was also determined. 
2. Materials and methods 
2.1. Materials 
REM was purchased from Echemi Pharma, Qingdao, China. The 
native βCD, the randomly substituted (SBEβCD DS ~ 6.5) and the 
single isomer per-6-sulfobutylated (per-6-SBEβCD DS = 7.0, [10]) βCD 
derivatives as well as three γCDs, native γCD, the randomly 
substituted SBEγCD (DS = 5.7) and the single isomer sugammadex  
[11] were products of CycloLab Ltd. (Budapest, Hungary). D2O 
(99.9 atom% D) and DMSO ( 99.7% HPLC grade) and DMSO-d6 (99.9 
atom% D) were purchased from Merck (Darmstadt, Germany). Other 
base chemicals of analytical grade were from commercial suppliers 
and were used without further purification. 
2.2. UV-pH titration 
500 mL stock solution was prepared by dissolving the appro-
priate amount of Na2HPO4 (15.0 mM) and HCO2NH4 (20 mM). The 
desired pH values ranging from 1.75 to 5.26 (14 individual samples) 
were adjusted by 6.0 M HCl and 6.0 M NaOH (pH was controlled by a 
Metrohm 913 pH meter combined with a standard glass electrode). 
Thereafter, 30 μL 15 mM REM DMSO stock solution was added to 
each 10 mL portion of the buffered samples at a given pH, while 
30 μL of DMSO were used in case of the blank solutions. UV-Vis 
spectra were recorded in the 220–400 nm range on a Unicam UV2 
UV/Vis Spectrometer at room temperature. The whole matrix of 
measured absorbances in the range of 227–345 nm (typically, 590 
wavelengths at each pH values) was involved in the computer eva-
luation using nonlinear regression as mentioned in the literature  
[12] by the OPIUM program [13] to yield the pKa of REM. 
2.3. NMR spectroscopy 
Nuclear magnetic resonance (NMR) spectroscopy measurements 
were carried out on a 600 MHz Varian DDR NMR spectrometer 
(Agilent Technologies, Palo Alto, CA, USA), equipped with a 5 mm 
inverse-detection probehead and a gradient module. Standard pulse 
sequences and processing routines available in VnmrJ 3.2 C/ 
Chempack 5.1 and MestreNova 14.2.0 were used. The complete re-
sonance assignments of REM and the CDs (Tables S1-2., Figs. S1-11.) 
were established from direct 1H–13C, long-range 1H–13C, and scalar 
spin-spin connectivities derived from 1D 1H, 2D 1H-1H gCOSY, 
zTOCSY (mixing time of 150 ms), ROESYAD (mixing time of 300 and 
400 ms), NOESY and 1H–13C gHSQCAD (1JCH = 140 Hz) experiments. 
The 1H chemical shifts were referenced to the methyl singlet 
(δ = 3.31 ppm) of internal CH3OH. All NMR spectra were acquired in 
standard 5 mm NMR tubes at 298 K. 
2.3.1. 1H NMR titration experiments 
The stoichiometry of REM complexation with various CDs was 
investigated by Job’s method of continuous variation [14]. Samples 
were prepared in acidic (D2O, HCl; pH 2.0) solutions at 298 K. The 
total molar concentration of the host and guest components 
+c cREM CD was kept constant at 1 mM, while the mole fraction of 
REM, =x cREM REM / +c c( )REM CD was varied gradually in 0.1 unit steps 
from 0 to 1. 1H chemical shifts REM were recorded at 600 MHz for 
several REM resonances and complexation-induced displacement 
values = | |REM REM REM were calculated with respect to REM
measured in the absence of CD. To construct Job’s plots, REM values 
were multiplied by the mole fraction of REM and depicted as a 
function of xREM. 
To determine the apparent and averaged - in the case of the 
random substituted CD derivatives - stability constant in each case, 
separate 1H NMR titrations were performed on acidic samples. For 
each βCD derivative 500 μL 1 mM REM was titrated with increasing 
portions (5–1000 μL) of CD stock solutions (10 mM βCD, 6.16 mM 
SBEβCD, 9.05 mM per-6-SBEβCD, 11.45 mM γCD, 6.16 mM SBEγCD) 
while in case of the native γCD 500 μL 0.45 mM REM was titrated 
with 10 mM γCD. Due to the poor solubility of sugammadex, the 
conditions were changed as follows: 500 μL of 0.2 mM REM solution 
was titrated with 5–600 μL of 0.66 mM sugammadex stock solution. 
Following equilibration, 1H NMR spectra were recorded in each ti-
tration step at 600 MHz and 298 K. Both titration datasets were 
analyzed by the following method. The experimental titration curves 
for well-resolved resonances of REM were evaluated by the Origin 
software, using the 1:1 REM:CD complex as confirmed by the Job’s 
method. If complexation occurs with rapid kinetics on the NMR 
chemical shift timescale, the observed chemical shift REM, i
obs of the ith 
carbon-bound proton in REM becomes a mole-fraction weighted 
average of the species-specific values in the uncomplexed REM 
( )REM,i and in the complex ( )REM CD,i , 
Fig. 1. Chemical structures and numbering of the remdesivir (A) and the studied β- and γ-cyclodextrin (7 and 8 glucose units) derivatives (B).  











where cCD and cREM denote equilibrium concentrations, while ctotal
CD
and ctotal
REM are the total concentrations of the compounds in the so-
lution [15]. 
Chemical shifts for all hydrogens (i) of REM were plotted as a 
function of VCD (μL) to select the resonances with sufficient sensi-
tivity (Δδ) to enter the evaluation. The selected datasets were fitted 
to the model described above, in order to determine the apparent 
complex stability constant (log K) values. 
2.3.2. NMR structural studies on complex formation 
To explore the spatial arrangement of the host-guest complexes, 
nuclear Overhauser effect (NOE) type experiments [16] were per-
formed on different molar ratio REM:CD samples under acidic con-
ditions (pH 2.0), at 298 K. 2D ROESY spectra were acquired on the 
600 MHz instrument, collecting 16 and 32 scans on 1258·512 data 
points, applying mixing times of 300 and 400 ms, respectively. 
3. Results and discussion 
3.1. Determination of REM’s pKa by UV-pH titration method 
Currently, there are no experimentally supported literature data 
on the pKa value of REM, only predicted (in silico) data are available  
[17], however, the protonation state influences its intermolecular 
interactions. Based on our observations, REM solubility significantly 
increases below pH 3.5, suggesting that protonation may occur in 
this region. Interestingly in reference [18], the predicted pKa value of 
REM (pKa 0.65) seems rather low, however the site of protonation is 
presumably the rare, yet basic aminopyrrolo-triazin moiety. As the 
aminopyrrolo-triazin part is the strongest chromophore of REM, the 
protonation of REM evokes an intense pH-dependent spectral shift. 
Consequently, UV-pH titration could be the first choice to provide a 
reliable pKa value. Fig. 2 shows the registered UV absorption spectra 
of REM at various pH values. Acidifying the solution results in hy-
pochromic and hypsochromic effects in the range of 240–250 nm, 
while hyperchromic and bathochromic effects could be observed in 
the range of 280–320 nm. The largest changes in the absorbance 
values were observed at ~245 and ~303 nm. To determine the exact 
pKa value, the whole matrix of measured absorbances was involved 
in the evaluation, titration curves were fitted simultaneously for all 
wavelengths (see inset of Fig. 2). This evaluation yielded a pKa = 3.56 
with an estimated standard deviation of 0.01. Therefore, at least 97% 
of REM molecules are present in monoprotonated form under pH 2.0 
conditions. 
3.2. Cyclodextrin complex stabilities of REM 
The complex stoichiometry and stability for all six CD-REM sys-
tems were assessed by NMR spectroscopy. The complete resonance 
assignments of REM can be found in Supporting Information Table 
S1. The most sensitive (showing the largest complexation induced 
chemical shift changes), non-overlapping and well-separated 1H 
NMR resonances of REM were observed in each case. In the case of 
βCD, Job’s plot curves (Supporting Information Fig. S12) show a 
maximum at x = 0.5, suggesting the formation of 1:1 complex stoi-
chiometry. Similarly, Job’s experiments were performed with the 
other CD derivatives (data not shown) confirming identical averaged 
stoichiometry. 
To determine the stability constants of CD-REM complexes, 
single-tube 1H NMR titrations were carried out in all cases. During 
the titration of REM with βCD, chemical shift variation of the fol-
lowing REM resonances was monitored: H1, H2, H7–8, H9–10, H11, 
H13, H15, H18–19 (Fig. 3A). In order to extract a robust and reliable 
Fig. 2. UV absorption spectra of REM recorded at different pH values and the titration curve at 302 nm, fitted simultaneously for each registered wavelength.  
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stability constant [19], all eight datasets were subjected to a si-
multaneous nonlinear regression using Origin software (Fig. 3B). 
This global evaluation yielded a logK = 3.06 with an estimated 
standard deviation of 0.01, a strong binding affinity for βCD. All the 
other chemical shift changes are depicted in Supporting Information 
Figs. S13–17., while the obtained stability values are summarized in  
Table 1. Comparing the native CDs, a tenfold decrease in stability 
could be observed when using γCD. Generally, the introduction of 
the anionic sulfobutylether-sidechains on the CD hosts contribute to 
a significant stability enhancement (more than fivefold for γCD, 
while tenfold increase for βCD, respectively), resulting in a high 
affinity system for REM and SBEβCD (averaged and apparent logK = 
3.99) [20]. It has also been revealed that the number of the anionic 
sidechains located on the primary side of the host plays a critical role 
in the stability of the inclusion complex. The single isomer sulfo-
butylether-CD (per-6-SBEβCD) results in an additional two-fold in-
crease in stability with the monoprotonated REM compared to the 
random SBEβCD, owing to the seven anionic sidechains located on 
the primary side of the host. Sugammadex is almost fully protonated 
under pH 2.0 conditions (in-house data) and possesses shorter 
sidechains than the sulfobutylether-CD derivatives, therefore limited 
electrostatic interactions can occur between the host and REM. The 
Fig. 3. Representative 1H NMR chemical shift changes of REM (subplot A) upon titration with βCD. Subplot B shows the selected titration profiles of REM H18–19 and H15, 
simultaneously fitted by the 1:1 complexation model using Origin program. 
Table 1 
Stability constant values of the investigated CD-REM complexes, determined by Origin software.          
βCD γCD SBEβCD 
(DS ~ 6.5) 
per6-SBEβCD 
(DS = 7.0) 
sugammadex 
(DS = 8.0) 
SBEγCD 
(DS ~ 5.7)  
logK 3.06 ± 0.01 2.08 ± 0.02 3.99 ± 0.02 * 4.35 ± 0.03 3.65 ± 0.04 2.77 ± 0.01 * 
* apparent stability constants due to the heterogenous nature of the cyclodextrin  
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obtained stability constant indicates a much weaker intermolecular 
interactions compared to the permanently negatively charged CDs. 
3.3. Structural characterization of REM-CD complexes by NMR 
To obtain atomic-level information on the 3D structure of the 
complexes 2D ROESY NMR experiments were carried out at various 
host-guest molar ratios. In the case of βCD, 2D ROESY spectrum was 
registered on a 1:3 (REM:βCD) system in order to ensure significant 
excess of the host. A zoomed inset in Fig. 4 refers spatial proximities 
between the ethylbutyl-sidechain of REM and βCD. Intermolecular 
cross-peaks could be detected between the REM’s methyl- (H18–19), 
the methylene- (H16-H17) and the inner cavity resonances of βCD 
(H3 and H5), proving that the aliphatic moiety immersed into the 
host cavity (Fig. 4). The encapsulation of alkyl chains is well-known 
in the literature, especially in the case of lipids [21]. As REM also 
possess a rather lipophilic phenoxy moiety too, its inclusion was also 
anticipated, however no inclusion of the phenoxy moiety was ob-
served. There are literature examples where the immersion of 
branched alkyl sidechains is preferred even in the presence of an 
aromatic moiety [22]. 
The inclusion of the ethylbutyl-sidechain was also corroborated 
by a further interaction between the methyl resonance of the alanyl 
residue (H13) and the H6 methylene of the βCD, which unequivocally 
confirms that the inclusion occurs from the narrower rim of the CD 
(see Fig. 4). 
The single isomeric nature and the concomitant simplicity of the 
NMR resonances of per-6-SBEβCD permitted the depiction of the 
spatial arrangement of REM-SBEβCD complex. The observed ROESY 
cross-peaks for the alanyl residue (H13) and the H6 resonances of 
per-6-SBEβCD assigned the direction of penetration of ethylbutyl- 
moiety of REM into the cavity from the primary side (see Supporting 
Information Fig. S18). Thus, the proposed arrangement allows the 
formation of electrostatic interactions between the CD’s negatively 
charged sulfobutyl-sidechains and the REM’s protonated 
heterocyclic moiety, thereby supporting the observed increase in 
complex stability. Our previous study [20] indicated, that the 
random substituted nature of SBEβCD makes difficult to determine 
the direction of REM’s inclusion (Fig. S19), however SBEβCD pos-
sesses a random substituted nature, i.e. carries sulfobutyl-sidechains 
at position 2, 3 and 6 as well. Taking into consideration the identical 
inclusion mode for both βCD and per-6-SBEβCD along with the sta-
bility values, herein we propose that the SBEβCD-REM complex is 
also constructed in the same fashion (see Fig. 5). 
The larger cavity of γCD is not perfectly suited for the ethyl-
butyl moiety, only weak intermolecular interactions could be 
observed in the 2D ROESY spectrum (see Supporting Information 
Fig. S20). However, clear evidences indicate that the phenoxy ring 
immerses into the cavity of γCD from its narrower side, supporting 
a weak interaction between γCD and REM (Fig. S20). The sulfo-
butylation of γCD resulted in stability enhancement, however, no 
conclusive complex structure could be derived due to broadened 
and diffuse NMR signals. In this case both aliphatic and aromatic 
parts of REM are involved in complexation (see Supporting 
Information Fig. S21). The single isomer γCD derivative su-
gammadex allowed a detailed NMR characterization of REM 
complexation at pH 2.0 (Supporting Information Fig. S22), where 
the most pronounced interaction was the immersion of the phe-
noxy moiety into the cavity from the wider rim (see Fig. 5.). Ad-
ditionally, weak interactions could be deduced between the 
methyl resonances of ethylbutyl-sidechain and those of the cavity 
protons suggesting the co-existence of a different binding mode as 
shown in Fig. 5. Moreover, the ethylthio groups of sugammadex 
show spatial proximity with the aliphatic chain of REM (Fig. S22), 
however, this interaction lacks real inclusion of REM into the 
cavity. The intermolecular interaction is therefore established 
through the peripheral (ethylthio) groups of sugammadex and the 
alkyl sidechain of REM. Thus, REM complexation with su-
gammadex accommodates several geometries leading to a 
superior stability. 
Fig. 4. Partial 2D ROESY spectrum of a 1:3 molar ratio (REM:βCD) sample and the structure of the suggested inclusion complex.  
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4. Conclusions 
In the present study intermolecular interactions of REM and 
various CD derivatives were characterized extensively by NMR 
spectroscopy. The aim of this study was to understand in details the 
molecular-level interactions between REM and its excipient in 
Veklury™ (SBEβCD) and with other cyclodextrin derivatives. NMR 
spectroscopic studies revealed that introduction of the anionic sul-
fobutylether-sidechains on the CD hosts contributes to a significant 
stability enhancement, furthermore the primary side sulfobutylation 
of the host plays the most critical role in the stability of the inclusion 
complex. Possible complex structures were determined by 2D ROESY 
NMR experiments and revealed that mainly the ethylbutyl moiety is 
involved in the molecular encapsulation in REM-βCD systems. 
Besides, the inclusion of the phenoxy moiety was only observed in 
the case of γCD derivatives. In addition, the pKa value of REM was 
determined experimentally by UV-pH titration method here for the 
first time. The pKa value of the heterocyclic aminopyrrolo-triazin 
moiety yielded a pKa value of 3.56. Our results also highlighted that 
the charge state of the host and the guest may remarkably con-
tribute to the inclusion complex formation of REM. As not only the 
formulation, but also the preparative scale purification and chiral 
analysis of REM poses several challenges for the analytical com-
munity our results may open the door of the application of cyclo-
dextrins in those fields as well. 
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